{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:37:35Z","timestamp":1747157855119,"version":"3.40.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clml.2024.05.021","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T05:58:02Z","timestamp":1717394282000},"page":"e336-e343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the Connect\u24c7 MM Registry"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1491-2548","authenticated-orcid":false,"given":"Rafat","family":"Abonour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1518","authenticated-orcid":false,"given":"Robert","family":"Rifkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Omel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Narang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Toomey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne I.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Terebelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Mouro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujith","family":"Dhanasiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2024.05.021_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2024.05.021_bib0002","first-page":"S3","article-title":"Current approaches to management of newly diagnosed multiple myeloma","volume":"97","author":"Goel","year":"2022","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2024.05.021_bib0003","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/jpm12091451","article-title":"Steps towards a multiple myeloma cure?","volume":"12","author":"Gozzetti","year":"2022","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.clml.2024.05.021_bib0004","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2024.05.021_bib0005","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.05.021_bib0006","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.clml.2024.05.021_bib0007","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14656566.2019.1577822","article-title":"The pharmacologic management of multiple myeloma in older adults","volume":"20","author":"Dempsey","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.clml.2024.05.021_bib0008","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2024.05.021_bib0009","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bjh.16139","article-title":"Development of a prognostic model for overall survival in multiple myeloma using the Connect\u24c7 MM Patient Registry","volume":"187","author":"Terebelo","year":"2019","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2024.05.021_bib0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.clml.2019.06.007","article-title":"Treatment patterns and clinical and economic outcomes in patients with newly diagnosed multiple myeloma treated with lenalidomide- and\/or bortezomib-containing regimens without stem cell transplant in a real-world setting","volume":"19","author":"Chari","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.clml.2024.05.021_bib0011","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41408-021-00524-1","article-title":"Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect\u24c7 MM Registry","volume":"11","author":"Lee","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2024.05.021_bib0012","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.05.021_bib0013","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.05.021_bib0014","doi-asserted-by":"crossref","first-page":"170","DOI":"10.46883\/ONC.2021.3504.0170","article-title":"Treatment considerations for transplant-ineligible multiple myeloma","volume":"35","author":"Elnair","year":"2021","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.clml.2024.05.021_bib0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O'Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.05.021_bib0016","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1182\/blood-2019-128000","article-title":"Updated results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (RVd-lite) in transplant-ineligible multiple myeloma","volume":"134","author":"O\u2019Donnell","year":"2019","journal-title":"Blood"},{"issue":"10068","key":"10.1016\/j.clml.2024.05.021_bib0017","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clml.2024.05.021_bib0018","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes","volume":"17","author":"Shah","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2024.05.021_bib0019","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3109\/10428194.2015.1132419","article-title":"Connect\u24c7 MM - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide","volume":"57","author":"Rifkin","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.clml.2024.05.021_bib0020","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ajh.24796","article-title":"Recognition of early mortality in multiple myeloma by a prediction matrix","volume":"92","author":"Terebelo","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2024.05.021_bib0021","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.clml.2014.12.002","article-title":"Connect\u24c7 MM Registry: the importance of establishing baseline disease characteristics","volume":"15","author":"Rifkin","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2024.05.021_bib0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.05.021_bib0023","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u24c7): multiple myeloma (Version 3.2024). [Accessed: March 24, 2024]; Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf."},{"issue":"1","key":"10.1016\/j.clml.2024.05.021_bib0024","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.05.021_bib0025","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1182\/blood-2021-153416","article-title":"Characteristics and outcomes of nontransplanted patients with newly diagnosed multiple myeloma (NDMM) initiating treatment with bortezomib, lenalidomide, and dexamethasone (VRd) as first-line of therapy","volume":"138","author":"Medhekar","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.05.021_bib0026","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12885-022-09980-9","article-title":"Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received bortezomib in combination with lenalidomide and dexamethasone as first line of therapy in the United States","volume":"22","author":"Medhekar","year":"2022","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.clml.2024.05.021_bib0027","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.05.021_bib0028","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2024.05.021_bib0029","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cam4.2656","article-title":"Connect\u24c7 MM Registry as a national reference for United States multiple myeloma patients","volume":"9","author":"Ailawadhi","year":"2020","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.clml.2024.05.021_bib0030","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.05.021_bib0031","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3390\/cancers15071929","article-title":"30 years of improved survival in non-transplant-eligible newly diagnosed multiple myeloma","volume":"15","author":"Chacon","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:10:44Z","timestamp":1729696244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2152265024002258"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the Connect\u24c7 MM Registry","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}